Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Ligand (LGND) Breakout! -- Ignore unavailable to you. Want to Upgrade?

To: Hippieslayer who wrote (12003)	12/2/1997 9:01:00 PM
From: David Bogdanoff	Read Replies (1) \| Respond to of 32384

To ALL; The most common reason, by far, for clinical study site selection is availability of suitable patients. In view of the rare nature of ctcl this is very likely why a polsih site was selected. A drug company typically selects a prominent clinical researcher in the appropriate specialty who also provides sites, and then adds on sites as needed. Typically some European sites are included to facilitate European submissions, but in some cases data from Europe is included for a US submission. If a company starts adding on sites in mid trials, it usually means that they are having trouble getting the patients from their original sites. It can also mean that some interim results are disappointing and they want more patients than originally planned for to increase the probability of a favorable outcome. Typically, the FDA will allow up to 20% additional patients for this purpose. David

To: Hippieslayer who wrote (12003)	12/3/1997 3:39:00 AM
From: Cheryl Galt	Read Replies (2) \| Respond to of 32384

> an astute person can see that the trading range of lgnd has predominantly been between roughly 9/9.5 and 17.5/18 for over a year. Astute or not, a person with a 5-year graph can see trading-range opportunities, and the potential for cave-ins available to all these exciting emerging biotechs. For the forseeable future, I suspect we will have occasional opportunities to buy positions at 12-13, or better. Multiple positions, monitoring volume, mental stops, controlling greedy impulses and wishful thinking, cautious optimism, healthy scepticism, Diversification, --- THAT's where the astute comes in, IMO. quote.yahoo.com Here's hoping that all the "mays" in the Lilly contract pan out, and that Lilly turns out to be a faithful suitor. Recent Lilly history in this regard leaves me feeling less than totally secure... Hence my motto: Expect the best, but be prepared for the worst. Happy trading/investing .... Cheryl